DB06020ExperimentalSmall molecule
XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
- Mechanism
- Curator reviewed
XEN-D0101 is a potassium channel modulator for the prevention of atrial fibrillation. It has been shown to have excellent activity in vivo and ex vivo models, and is highly atrium-selective.
- Primary indication
- Investigated for use/treatment in atrial fibrillation.Curator reviewed
- Code names
- XEN-D0101
Resolves to
Targets
What you can answer from here — as of July 03, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with XEN-D0101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account